<DOC>
	<DOCNO>NCT00170950</DOCNO>
	<brief_summary>A comparison study two combination drug , amlodipine/benazepril benazepril/HCTZ evaluate effectiveness combination reduce heart disease death high risk hypertensive population .</brief_summary>
	<brief_title>Avoiding Cardiovascular Events Through Combination Therapy Patients Living With Systolic Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Benazepril</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>At least 55 year age . Previously untreated treated hypertension . For patient &gt; = 60 year , evidence least one CV disease target organ damage , patient 5559 year evidence least two CV disease target organ damage two different organ system define protocol . Allergy drug administer trial . Current angina pectoris ( ie , anginal event require NTG within 1 month prior Visit 1 ) . Secondary hypertension . Refractory hypertension define SBP &gt; = 180 mmHg and/or DBP &gt; = 110 mmHg unresponsive tripledrug regimen sympatholytics , diuretic vasodilator . History symptomatic heart failure ( NYHA class IIIV ) ejection fraction &lt; 40 % . Myocardial infarction , coronary revascularization ( CABG PCI ) , unstable angina within one month Visit 1 . Stroke transient ischemic event ( TIA ) within 3 month Visit 1 . Significant obstructive valvular cardiovascular disease valvular disease expect lead surgery course study . Evidence hepatic disease ( AST ALT value &gt; = 2 X upper limit normal ) . Impaired renal function ( serum creatinine &gt; = 2.5 mg/dL ( 221 µmol/L ) ) . Baseline serum potassium &gt; 5.2 meq/L potassium supplement . History malignancy include leukemia lymphoma ( basal cell skin cancer ) within last 5 year . History clinically significant auto immune disorder Systemic Lupus Erythematosus . Significant noncardiovascular illness condition likely result death prior trial completion , e.g. , major organ transplant ( life expectancy &lt; 5 year ) . Significant cardiovascular disease aortic aneurysm ≥ 6 cm , likely require surgical intervention course study . Other protocoldefined exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>cardiovascular morbidity</keyword>
	<keyword>cardiovascular mortality</keyword>
	<keyword>benazepril</keyword>
	<keyword>amlodipine</keyword>
	<keyword>high risk population</keyword>
</DOC>